Rhythm Biosciences Ltd (ASX: RHY) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Rhythm Biosciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$23.25 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
283.60 million
Earnings per share
-0.030
Dividend per share
N/A
Year To Date Return
-37.96%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Rhythm Biosciences Ltd (ASX: RHY)
Latest News
Healthcare Shares
These were the best performing ASX healthcare shares in October
Healthcare Shares
Here's why the Rhythm Biosciences share price (ASX:RHY) is jumping higher today
Share Gainers
Why is the Rhythm Biosciences (ASX:RHY) share price up 11% on Monday?
Healthcare Shares
Why is the Rhythm (ASX:RHY) share price climbing 10% today?
Share Gainers
Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price is jumping 8% today
Healthcare Shares
Why the Rhythm Biosciences (ASX:RHY) share price is flying higher today
Share Gainers
Why ARB, Rhythm Biosciences, Sezzle, & Spark shares are storming higher
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price is racing 6% higher
Healthcare Shares
Why the Rhythm (ASX:RHY) share price is climbing today
Healthcare Shares
Here's why the Rhythm (ASX:RHY) share price is soaring 8% today
Healthcare Shares
Rhythm (ASX:RHY) share price surges 10% on ColoSTAT results
RHY ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
RHY Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Dec 2024 | $0.09 | $0.00 | 0.00% | 1,005,731 | $0.08 | $0.09 | $0.08 |
| 17 Dec 2024 | $0.08 | $0.00 | 0.00% | 30,744 | $0.08 | $0.08 | $0.08 |
| 16 Dec 2024 | $0.08 | $0.00 | 0.00% | 611,800 | $0.08 | $0.08 | $0.08 |
| 13 Dec 2024 | $0.08 | $0.00 | 0.00% | 213,551 | $0.09 | $0.09 | $0.08 |
| 12 Dec 2024 | $0.09 | $0.00 | 0.00% | 302,538 | $0.09 | $0.09 | $0.09 |
| 11 Dec 2024 | $0.09 | $0.00 | 0.00% | 47,844 | $0.09 | $0.09 | $0.09 |
| 10 Dec 2024 | $0.09 | $0.00 | 0.00% | 15,101 | $0.09 | $0.09 | $0.09 |
| 09 Dec 2024 | $0.09 | $0.00 | 0.00% | 233,838 | $0.09 | $0.09 | $0.09 |
| 06 Dec 2024 | $0.09 | $0.00 | 0.00% | 163,426 | $0.09 | $0.09 | $0.09 |
| 05 Dec 2024 | $0.09 | $-0.01 | -10.64% | 455,368 | $0.09 | $0.09 | $0.09 |
| 04 Dec 2024 | $0.09 | $0.01 | 11.76% | 792,396 | $0.09 | $0.09 | $0.09 |
| 03 Dec 2024 | $0.09 | $0.00 | 0.00% | 65,326 | $0.09 | $0.09 | $0.09 |
| 02 Dec 2024 | $0.09 | $-0.01 | -10.87% | 642,493 | $0.09 | $0.09 | $0.09 |
| 29 Nov 2024 | $0.09 | $0.00 | 0.00% | 927,681 | $0.09 | $0.09 | $0.09 |
| 28 Nov 2024 | $0.09 | $0.00 | 0.00% | 489,195 | $0.09 | $0.09 | $0.09 |
| 27 Nov 2024 | $0.09 | $-0.01 | -10.20% | 463,404 | $0.10 | $0.10 | $0.09 |
| 26 Nov 2024 | $0.10 | $0.00 | 0.00% | 1,991,062 | $0.09 | $0.10 | $0.09 |
| 25 Nov 2024 | $0.10 | $-0.03 | -23.08% | 1,082,293 | $0.12 | $0.12 | $0.10 |
| 22 Nov 2024 | $0.13 | $-0.01 | -7.14% | 222,016 | $0.13 | $0.14 | $0.12 |
| 21 Nov 2024 | $0.14 | $0.01 | 7.69% | 548,915 | $0.14 | $0.14 | $0.13 |
| 20 Nov 2024 | $0.13 | $0.01 | 8.33% | 195,271 | $0.12 | $0.13 | $0.12 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Jul 2024 | Otto Buttula | Expiry | 1,342,500 | $71,152 |
Options expired.
|
| 31 Jul 2024 | Louis (Lou) Panaccio | Expiry | 85,000 | $4,505 |
Options expired.
|
| 31 Jul 2024 | Trevor Lockett | Expiry | 252,000 | $13,356 |
Options expired.
|
| 14 Jun 2024 | Otto Buttula | Buy | 600,000 | $40,408 |
On-market trade.
|
| 03 Jun 2024 | Otto Buttula | Buy | 276,906 | $18,984 |
On-market trade.
|
| 27 May 2024 | Otto Buttula | Buy | 546,273 | $37,392 |
On-market trade.
|
| 21 Mar 2024 | Otto Buttula | Issued | 10,850,000 | $1,085,000 |
Rights issue.
|
| 21 Mar 2024 | Otto Buttula | Issued | 5,425,001 | $542,500 |
Rights issue.
|
| 21 Mar 2024 | Trevor Lockett | Issued | 193,650 | $19,365 |
Rights issue.
|
| 21 Mar 2024 | Trevor Lockett | Issued | 387,300 | $38,730 |
Rights issue.
|
| 21 Mar 2024 | Louis (Lou) Panaccio | Issued | 249,000 | $24,900 |
Rights issue.
|
| 21 Mar 2024 | Louis (Lou) Panaccio | Issued | 124,500 | $12,450 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Otto Leslie Steven Buttula | Executive ChairmanExecutive Director | Oct 2019 |
Mr Buttula has had experience and success in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula's executive experience includes co-founder and CEO and Managing Director of IWL Ltd, an online financial services company that listed on the ASX in 1999. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Ltd.
|
| Dr David Atkins | Chief Executive OfficerManaging Director | May 2024 |
--
|
| Mr Gavin Fox-Smith | Non-Executive Director | Dec 2024 |
Mr Fox-Smith has been a leader and champion of Medical Technology across Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is advocate for Gender Equality and Indigenous Engagement. His career spans over 35 years, previously holding the position of Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices, Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum. Gavin is currently transitioning out of his executive CEO role at Omnigon, a private Australian company in the Ostomy Care market. He is currently, Chair of ANDHealth (Australias National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation. Gavin is a member of the Champions of Change Coalition STEM/Health group and serves as Ambassador for Rotary Oceania Medical Aid for Children (ROMAC).
|
| Ms Andrea Steele | Company SecretaryGeneral Counsel | Feb 2022 |
-
|
| Mr James Stephen Barrie | Joint Company Secretary | Dec 2023 |
-
|
| Andrea Steele | Company SecretaryGeneral Counsel |
-
|
|
| Guy Carisbrooke | Financial Controller |
-
|
|
| James Stephen Barrie | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Webinvest Pty Ltd | 22,479,168 | 9.04% |
| Newfound Investments Pty Ltd | 13,905,407 | 5.59% |
| Ferndale Securities Pty Ltd | 10,300,000 | 4.14% |
| HSBC Custody Nominees (Australia) Limited | 9,269,796 | 3.73% |
| Loumea Investment Pty Ltd | 8,052,520 | 3.24% |
| Northern Star Nominees Pty Ltd | 7,380,000 | 2.97% |
| Rojo Nero Capital Pty Ltd | 4,213,751 | 1.70% |
| Giokir Pty Ltd | 3,661,470 | 1.47% |
| Mr Hsien Michael Soo | 3,305,403 | 1.33% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 3,000,000 | 1.21% |
| DC & PC Holdings Pty Ltd | 2,688,156 | 1.08% |
| Commonwealth Scientific & Industrial Research Organisation | 2,500,000 | 1.01% |
| Ms Natalie Louise Patterson | 2,477,083 | 1.00% |
| E & W Nominee Pty Ltd | 2,207,941 | 0.89% |
| Mr Daniel Eddington & Mrs Julie Eddington | 2,123,532 | 0.85% |
| Mr Wei Feng & Mrs Jie Liu | 2,050,215 | 0.82% |
| Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison | 2,000,000 | 0.80% |
| Ardroy Securities Pty Ltd | 1,857,040 | 0.75% |
| BNP Paribas Nominees Pty Ltd ACF Clearstream | 1,775,214 | 0.71% |
| Mrs Linda Jane Lockett & Dr Trevor John Lockett | 1,678,300 | 0.68% |
